NCI Topic 290: siRNA Resource for Synthetic Lethal Screening of DNA Repair and Damage Signaling Networks
A promising direction in the development of anti-cancer drugs with high specificity and low toxicity is the possibility of inhibiting the functions of synthetically lethal (SL) (synergistic) DNA Damage and Repair (DDR) drug targets that are specifically modulated in cancer development. Under NIH SBIR contract HHSN261201200065C, we developed the technology for the construction of novel bi-specific pooled lentiviral shRNA libraries designed for the combinatorial knockdown of any two targets in a set of rationally selected genes. Furthermore, we successfully demonstrated the application of a set of bi-specific SL DDR shRNA libraries to detect SL binary interactions between 360 DDR genes in a panel of cancer cell lines.
The premade Bi-specific SL DDR pooled lentiviral shRNA libraries in plasmid format and the 360 DDR Relational Database with annotated gene information, reference SL gene interactions revealed in RNAi combinatorial screens, and predicted signaling pathway models are available to academic and non-profit researchers under MTA at no charge.
Please visit the Bi-Specific SL DDR shRNA Library Project Summary page for more information.
The DECIPHER RNAi screening platform was an open source project created by Cellecta to provide tools for researchers to perform and analyze comprehensive shRNA knockdown screens and to develop a standardized, yet versatile platform for collecting and comparing results from different studies and labs. The DECIPHER RNAi screening platform aided and continues to aid researchers interested in functional annotation of signaling networks, interpretation of viability screening and expression profiling results, and collaboration with other DECIPHER Project members. Development of the DECIPHER libraries was funded in part by several NIH grants (CA098374, NCRR RR024095, NHGRI HG003355, NCI CA134062, NCI CA141848) and distributed in plasmid form to academic and non-profit researchers under MTA at no charge. For a list of participating institutions and publications, visit the DECIPHER Mission page.
Although Cellecta is no longer offering the DECIPHER pooled lentiviral shRNA libraries under MTA, they can be purchased at a discounted rate for academic and non-profit researchers. For more information, see the DECIPHER shRNA Libraries page on the Cellecta website.
The DECIPHER Project was established by Cellecta, Inc. under collaboration and joint grants with the Fred Hutchinson Cancer Research Center, the Roswell Park Cancer Institute, and The Scripps Research Institute. We would like to acknowledge Dr. Gus Frangou from the FHCRC and Dr. Andrei Gudkov of the RPCI for their invaluable contributions and scientific expertise.
We also wish to acknowledge Agilent Technologies for granting us exclusive, early-access to their Oligo Library Synthesis technology for shRNA library applications.
Addgene helps distribute DECIPHER
DECIPHER Human Module 3 is released
View the DECIPHER Project Launch Press Release